Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study

被引：0
|
作者：
Jean-Luc Raoul
Jean-Luc Van Laethem
Marc Peeters
Catherine Brezault
Fares Husseini
Laurent Cals
Johannes Nippgen
Anja-Helena Loos
Philippe Rougier
机构：
[1] Digestive Oncology Department,Gastroenterology Department
[2] Centre E Marquis,undefined
[3] Hôpital Universitaire Erasme,undefined
[4] Ghent University Hospital,undefined
[5] Hôpital Cochin,undefined
[6] Hôpital Pasteur,undefined
[7] Oncology Service,undefined
[8] Hôpital Font Pré,undefined
[9] BP1412,undefined
[10] Merck KGaA,undefined
[11] Hôpital Ambroise Paré,undefined
来源：
BMC Cancer | / 9卷
关键词：
Epidermal Growth Factor Receptor; Irinotecan; Cetuximab; Folinic Acid; Epidermal Growth Factor Receptor Expression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] THE ROLE OF FOLINIC ACID IN COMBINATION WITH 5-FLUOROURACIL IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    WILKE, H
    HARSTRICK, A
    SEEBER, S
    ONKOLOGIE, 1995, 18 (01): : 65 - 67
  • [42] Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer
    McWilliams, Robert R.
    Goetz, Matthew P.
    Morlan, Bruce W.
    Salim, Muhammad
    Rowland, Kendrith M.
    Krook, James E.
    Ames, Matthew M.
    Erlichman, Charles
    CLINICAL COLORECTAL CANCER, 2007, 6 (07) : 516 - 521
  • [43] Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil folinic acid in the treatment of metastatic breast cancer: An interim analysis
    Klaassen, U
    Wilke, H
    Philippou, P
    Strumberg, PD
    Harstrick, A
    Eberhardt, W
    Becher, R
    Diergarten, K
    Seeber, S
    SEMINARS IN ONCOLOGY, 1995, 22 (06) : 7 - 11
  • [44] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer: Final results
    Kopetz, S.
    Glover, K.
    Eng, C.
    Wolff, R.
    Chang, D.
    Adinin, R.
    Morris, J.
    Abbruzzese, S.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2007, 18 : VII80 - VII80
  • [45] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
    Jo, H.
    Lee, M-S
    Lee, Y-P
    Kim, H.
    Hong, J. Y.
    Lee, J.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    Kim, S. T.
    CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
  • [46] Feasibility survey (phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer
    Focan, C
    Kreutz, F
    Graas, MP
    Longrée, L
    Moeneclaey, N
    David, A
    Focan-Henrard, D
    PATHOLOGIE BIOLOGIE, 2005, 53 (05): : 277 - 280
  • [47] A randomized phase II study of irinotecan, 5-fluorouracil, and folinic acid (FOLFIRI) with or without the addition of an endothelin receptor antagonist in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.
    Thomas, A. L.
    Wilson, R. H.
    Steward, W. P.
    Adams, R. A.
    Bridges, S. E.
    Casbard, A. C.
    Maughan, T.
    Griffiths, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [48] Phase I study of ursodeoxycholic acid in combination with 5-fluorouracil, leucovorin, oxaliplatin, and bevacizumab for metastatic colorectal cancer
    Lai, Lily L.
    Chiu, Ken
    Lim, Dean
    Chao, Joseph
    Frankel, Paul Henry
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [49] Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
    Thomas Kuehr
    Paul Ruff
    Bernardo L Rapoport
    Stephen Falk
    Francis Daniel
    Conrad Jacobs
    Neville Davidson
    Josef Thaler
    Blandine Boussard
    James Carmichael
    BMC Cancer, 4
  • [50] Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer
    Kuehr, T
    Ruff, P
    Rapoport, BL
    Falk, S
    Daniel, F
    Jacobs, C
    Davidson, N
    Thaler, J
    Boussard, B
    Carmichael, J
    BMC CANCER, 2004, 4 (1)
12345